Verastem (VSTM) Operating Income (2011 - 2026)
Verastem's quarterly Operating Income came in at -$44.9 million in Q1 2026, down 1.64% year-on-year from -$45.6 million in Q1 2025, and down 153.03% quarter-over-quarter from $84.7 million in Q4 2025.
Verastem has reported Operating Income for 16 years, with the latest figure at -$44.9 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 1.64% year-over-year to -$44.9 million; the trailing twelve-month figure through Mar 2026 stood at -$44.7 million (up 65.89% YoY), and the FY2025 full-year result was -$44.0 million, up 61.73% from the prior year.
- Operating Income for Q1 2026 stood at -$44.9 million, down from $84.7 million in the prior quarter.
- The five-year high for Operating Income was $84.7 million in Q4 2025, with the low at -$44.9 million in Q1 2026.
- Average Operating Income over 5 years is -$21.7 million, with a median of -$21.4 million recorded in 2022.
- Peak annual rise in Operating Income reached 368.01% in 2025, while the deepest fall reached 139.45% in 2025.
- Tracing VSTM's Operating Income over 5 years: stood at -$16.8 million in 2022, then slumped by 84.85% to -$31.1 million in 2023, then slipped by 1.45% to -$31.6 million in 2024, then jumped by 368.01% to $84.7 million in 2025, then tumbled by 153.03% to -$44.9 million in 2026.
- The last three Operating Income figures came in at -$44.9 million (Q1 2026), $84.7 million (Q4 2025), and -$40.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | -44.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.90 Mn |
| Dec 31, 2025 | 84.67 Mn |
| Sep 30, 2025 | -40.72 Mn |
| Jun 30, 2025 | -43.76 Mn |
| Mar 31, 2025 | -44.17 Mn |
| Dec 31, 2024 | -31.59 Mn |
| Sep 30, 2024 | -37.03 Mn |
| Jun 30, 2024 | -18.28 Mn |
| Mar 31, 2024 | -28.06 Mn |
| Dec 31, 2023 | -31.14 Mn |
| Sep 30, 2023 | -21.31 Mn |
| Jun 30, 2023 | -20.29 Mn |
| Mar 31, 2023 | -19.34 Mn |
| Dec 31, 2022 | -16.85 Mn |
| Sep 30, 2022 | -17.71 Mn |
| Jun 30, 2022 | -21.40 Mn |
| Mar 31, 2022 | -16.98 Mn |
| Dec 31, 2021 | -16.51 Mn |
| Sep 30, 2021 | -14.85 Mn |
| Jun 30, 2021 | -15.94 Mn |
| Mar 31, 2021 | -14.11 Mn |
| Dec 31, 2020 | -16.75 Mn |
| Sep 30, 2020 | 15.02 Mn |
| Jun 30, 2020 | -21.26 Mn |
| Mar 31, 2020 | -26.36 Mn |
| Dec 31, 2019 | -33.29 Mn |
| Sep 30, 2019 | -26.10 Mn |
| Jun 30, 2019 | -38.28 Mn |
| Mar 31, 2019 | -34.67 Mn |
| Dec 31, 2018 | -34.26 Mn |
| Sep 30, 2018 | -21.57 Mn |
| Jun 30, 2018 | -18.19 Mn |
| Mar 31, 2018 | -20.76 Mn |
| Dec 31, 2017 | -18.05 Mn |
| Sep 30, 2017 | -23.14 Mn |
| Jun 30, 2017 | -13.47 Mn |
| Mar 31, 2017 | -13.15 Mn |
| Dec 31, 2016 | -11.80 Mn |
| Sep 30, 2016 | -8.06 Mn |
| Jun 30, 2016 | -8.71 Mn |
| Mar 31, 2016 | -8.43 Mn |
| Dec 31, 2015 | -11.96 Mn |
| Sep 30, 2015 | -15.53 Mn |
| Jun 30, 2015 | -15.46 Mn |
| Mar 31, 2015 | -15.24 Mn |
| Dec 31, 2014 | -14.00 Mn |
| Sep 30, 2014 | -13.39 Mn |
| Jun 30, 2014 | -13.09 Mn |
| Mar 31, 2014 | -13.13 Mn |
| Dec 31, 2013 | -11.39 Mn |
| Sep 30, 2013 | -10.64 Mn |
| Jun 30, 2013 | -10.28 Mn |
| Mar 31, 2013 | -9.08 Mn |
| Dec 31, 2012 | -7.98 Mn |
| Sep 30, 2012 | -10.43 Mn |
| Jun 30, 2012 | -6.90 Mn |
| Mar 31, 2012 | -6.93 Mn |
| Dec 31, 2011 | -6.02 Mn |
| Sep 30, 2011 | -4.05 Mn |
| Jun 30, 2011 | -2.49 Mn |
| Mar 31, 2011 | -1.15 Mn |